Ownership Capital B.V. Trims Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Ownership Capital B.V. trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 264,397 shares of the medical research company's stock after selling 5,805 shares during the period. Thermo Fisher Scientific accounts for about 5.1% of Ownership Capital B.V.'s holdings, making the stock its 9th largest holding. Ownership Capital B.V. owned about 0.07% of Thermo Fisher Scientific worth $137,547,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Corps Capital Advisors LLC purchased a new position in Thermo Fisher Scientific during the 4th quarter worth approximately $1,148,000. Private Wealth Partners LLC increased its holdings in shares of Thermo Fisher Scientific by 5.3% in the 4th quarter. Private Wealth Partners LLC now owns 63,203 shares of the medical research company's stock valued at $32,880,000 after acquiring an additional 3,197 shares during the period. Bryn Mawr Capital Management LLC increased its holdings in shares of Thermo Fisher Scientific by 214.6% in the 4th quarter. Bryn Mawr Capital Management LLC now owns 35,183 shares of the medical research company's stock valued at $18,303,000 after acquiring an additional 24,001 shares during the period. Financial Perspectives Inc increased its holdings in shares of Thermo Fisher Scientific by 119.6% in the 4th quarter. Financial Perspectives Inc now owns 459 shares of the medical research company's stock valued at $239,000 after acquiring an additional 250 shares during the period. Finally, Strata Wealth Advisors LLC increased its holdings in shares of Thermo Fisher Scientific by 6.6% in the 4th quarter. Strata Wealth Advisors LLC now owns 422 shares of the medical research company's stock valued at $220,000 after acquiring an additional 26 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Raymond James reaffirmed an "outperform" rating and issued a $667.00 target price (up from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. Robert W. Baird lowered their price target on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating on the stock in a research note on Thursday, October 24th. Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 price objective on the stock in a research report on Friday, January 10th. Morgan Stanley boosted their price objective on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an "overweight" rating in a research report on Friday, January 31st. Finally, StockNews.com upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, January 14th. Four analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $658.00.

Thermo Fisher Scientific Trading Down 1.0 %

TMO traded down $5.28 on Friday, reaching $532.55. 1,613,862 shares of the company's stock were exchanged, compared to its average volume of 2,087,588. The company's 50 day moving average is $548.36 and its 200-day moving average is $568.15. The company has a market cap of $203.70 billion, a price-to-earnings ratio of 32.22, a PEG ratio of 2.95 and a beta of 0.77. Thermo Fisher Scientific Inc. has a twelve month low of $493.30 and a twelve month high of $627.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be given a $0.43 dividend. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date is Friday, March 14th. This represents a $1.72 annualized dividend and a yield of 0.32%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.44%.

Thermo Fisher Scientific declared that its board has approved a stock buyback plan on Friday, November 15th that allows the company to buyback $4.00 billion in shares. This buyback authorization allows the medical research company to repurchase up to 2% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's management believes its stock is undervalued.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the completion of the transaction, the chief executive officer now directly owns 111,192 shares in the company, valued at approximately $58,960,669.92. This represents a 8.25 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the transaction, the executive vice president now owns 16,363 shares of the company's stock, valued at approximately $9,582,009.17. This trade represents a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 20,125 shares of company stock valued at $11,231,699 over the last 90 days. 0.34% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.